Pineoblastoma

Last updated
Pineoblastoma
Other namesPineoblastoma
Specialty Oncology   OOjs UI icon edit-ltr-progressive.svg
Symptoms Nausea, vomiting, headache, double vision, problems with eye movement [1]
Usual onsetChildhood, between the ages of 20 and 40 [1]
FrequencyJust under half of all pineal gland tumors, which make up fewer than 1% of all primary brain tumors [1]
Pineoblastoma on brain imaging Pineoblastoma.jpg
Pineoblastoma on brain imaging

Pineoblastoma is a malignant tumor of the pineal gland. A pineoblastoma is a supratentorial midline primitive neuroectodermal tumor. [2] Pineoblastoma can present at any age, but is most common in young children. They account for 0.001% of all primary CNS neoplasms. [3]

Contents

Epidemiology

Pineoblastomas typically occur at very young ages. One study found the average age of presentation to be 4.3 years, with peaks at age 3 and 8. [3] Another cites cases to more commonly occur in patients under 2 years of age. [4] Rates of occurrence for males and females are similar, but may be slightly more common in females. [4] [3] One study found incidence of pineoblastoma to be increased in black patients compared to white patients by around 71%. [5] This difference was most apparent in patients aged 5 to 9 years old.

Pathophysiology

The pineal gland is a small organ in the center of the brain that is responsible for controlling melatonin secretion. [2] Several tumors can occur in the area of the pineal gland, with the most aggressive being pineoblastoma. Pineoblastomas arise from embryonal cells in the pineal gland and are rapidly growing. They are considered grade 4 tumors, meaning they are malignant and may metastasize. [6] Due to the pineal gland's location at the center of the brain and the rapidly growing nature of this disease, obstruction of CNS fluid is a common symptom.

The exact cause of pineoblastoma is unknown. MicroRNA dysregulation has been found to be associated with many cases of pineoblastoma, specifically, mutations in DICER1 and DROSHA genes. [7] DICER1 germline mutations cause a tumor predisposition syndrome, and should be considered in patients with pineoblastoma. [8]

Pineoblastoma may occur in patients with hereditary uni- or bilateral retinoblastoma. When retinoblastoma patients present with pineoblastoma this is characterized as "trilateral retinoblastoma". [9] Up to 5% of patients with hereditary retinoblastoma are at risk of developing trilateral retinoblastoma. [10] This tumor combination is more aggressive than an isolated pineoblastoma. [4] Prognosis of patients with trilateral retinoblastoma is dismal, only a few patients have survived more than 5 years after diagnosis; all survivors were diagnosed with small tumors in a subclinical stage. [11] Recent advances in (high-dose) chemotherapy treatment regimens and early detection have improved survival of patients with trilateral retinoblastoma to up to 50%. [10]

Additionally, various mutations or deletions in chromosomes 1, 9, 13, 16 and 22 have been associated with pineoblastoma incidence. [3]

Clinical features

The most common symptoms to occur with pineoblastoma are headache, behavior changes, and cognitive disturbances. [12] These masses also often cause obstructive hydrocephalus, leading to increased intracranial pressure. This can result in vision changes and Parinaud's syndrome. [3]

Due to the aggressive nature of the disease, tumor spread at the time of diagnosis is common. [13] Pineoblastomas often invades locally, with spread to the head and spine seen in 25–41% of patients. [3] While CNS spread is relatively common, these tumors rarely cause distant metastases. [14]

Diagnosis

Histology of pineoblastoma Pineoblastoma HE x200.jpg
Histology of pineoblastoma

Several imaging methods can be used to diagnose pineoblastoma. Initially, urgent CTs are recommended, followed by MR imaging. [13] CT will show large, multilobulated masses with heterogenous contrast enhancement and peripheral calcification of the pineal gland. [4] [3] On MRI, pineoblastomas again appear as masses with heterogenous enhancement. They often appear hypo- to isointense on T1 and slightly hyperintense on T2-weighted images. Some areas of necrosis or hemorrhage may be seen as well. PET-CT has also been used in diagnosis, and shows increased uptake of fludeoxyglucose with pineoblastomas compared to other pineal masses.

Diagnosis also requires CSF sampling via lumbar puncture to assess for cytology and tumor markers. [13]

Biopsy is required for diagnosis. Pineoblastomas appear as high grade, highly cellular, small blue cells histologically. Features of aggressive malignancies can be seen, like high nucleus-to-cytoplasm ration, poorly differentiated cells, high mitotic activity, and necrosis. [13] [3] Homer Wright, or neuroblastic, and Flexner-Wintersteiner, or retinoblastic, rosettes can also be seen. In contrast to other masses of the pineal gland, pineocytomatous rosettes are not present. [13] Immunohistochemistry staining will reveal neuronal, glial, and photoreceptor marker positivity. This includes synaptophysin, neurofilament protein, and CRX, a specific pineal or retinal marker, positive staining. [13] [7]

Treatment

Initial treatment for pineoblastoma often includes a shunting procedure to redirect accumulated cerebrospinal fluid secondary to obstructive hydrocephalus. [2] This shunt can help manage increased intracranial pressure and relieve some symptoms. Surgery to remove the tumor is associated with better outcomes, however, this is not always possible due to the proximity of the pineal gland to neurovascular structures. [3] Complete tumor resection is only seen in about 30% of cases. Following surgery, radiation therapy to the brain and spinal cord can increase survival. [2] However, radiation can only safely be used in patients over 3 years old due to the risk of significant neurological impairment. Chemotherapy treatment can also be used, either before or after surgery; its optimal use is still under investigation. [3]

Prognosis

Pineoblastomas are very aggressive tumors. 5-year survival for patients with pineoblastomas is around 58%. [13] Prognosis for patients under 5 years old is lower, between 15 and 40%. [3] Disseminated disease at diagnosis is also associated with worse outcomes. When pineoblastomas occur with retinoblastomas, the prognosis is typically worse, and these patients require more aggressive treatment. [4]

Complete gross tumor resection is associated with improved prognosis, but is difficult and rare to achieve. Radiation therapy after surgery is also linked to improved survival. [3]

Related Research Articles

<span class="mw-page-title-main">Brain tumor</span> Neoplasm in the brain

A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors: malignant (cancerous) tumors and benign (non-cancerous) tumors. These can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. All types of brain tumors may produce symptoms that vary depending on the size of the tumor and the part of the brain that is involved. Where symptoms exist, they may include headaches, seizures, problems with vision, vomiting and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness.

<span class="mw-page-title-main">Retinoblastoma</span> Cancerous tumor of the developing eye

Retinoblastoma (Rb) is a rare form of cancer that rapidly develops from the immature cells of a retina, the light-detecting tissue of the eye. It is the most common primary malignant intraocular cancer in children, especially those under 3 years old.

<span class="mw-page-title-main">Ependymoma</span> Medical condition

An ependymoma is a tumor that arises from the ependyma, a tissue of the central nervous system. Usually, in pediatric cases the location is intracranial, while in adults it is spinal. The common location of intracranial ependymomas is the floor of the fourth ventricle. Rarely, ependymomas can occur in the pelvic cavity.

<span class="mw-page-title-main">Germ cell tumor</span> Medical condition

Germ cell tumor (GCT) is a neoplasm derived from the primordial germ cells. Germ-cell tumors can be cancerous or benign. Germ cells normally occur inside the gonads. GCTs that originate outside the gonads may be birth defects resulting from errors during development of the embryo.

<span class="mw-page-title-main">Blastoma</span> Type of cancer arising from precursor cells

A blastoma is a type of cancer, more common in children, that is caused by malignancies in precursor cells, often called blasts. Examples are nephroblastoma, medulloblastoma, and retinoblastoma. The suffix -blastoma is used to imply a tumor of primitive, incompletely differentiated cells, e.g., chondroblastoma is composed of cells resembling the precursor of chondrocytes.

<span class="mw-page-title-main">Medulloblastoma</span> Most common type of primary brain cancer in children

Medulloblastoma is a common type of primary brain cancer in children. It originates in the part of the brain that is towards the back and the bottom, on the floor of the skull, in the cerebellum, or posterior fossa.

<span class="mw-page-title-main">Primary central nervous system lymphoma</span> Medical condition

Primary central nervous system lymphoma (PCNSL), also termed primary diffuse large B-cell lymphoma of the central nervous system (DLBCL-CNS), is a primary intracranial tumor appearing mostly in patients with severe immunodeficiency. It is a subtype and one of the most aggressive of the diffuse large B-cell lymphomas.

Malignant rhabdoid tumour (MRT) is a very aggressive form of tumour originally described as a variant of Wilms' tumour, which is primarily a kidney tumour that occurs mainly in children.

<span class="mw-page-title-main">Germinoma</span> Medical condition

A germinoma is a type of germ-cell tumor, which is not differentiated upon examination. It may be benign or malignant.

<span class="mw-page-title-main">Atypical teratoid rhabdoid tumor</span> Medical condition

An atypical teratoid rhabdoid tumor (AT/RT) is a rare tumor usually diagnosed in childhood. Although usually a brain tumor, AT/RT can occur anywhere in the central nervous system (CNS), including the spinal cord. About 60% will be in the posterior cranial fossa. One review estimated 52% in the posterior fossa, 39% are supratentorial primitive neuroectodermal tumors (sPNET), 5% are in the pineal, 2% are spinal, and 2% are multifocal.

A paraneoplastic syndrome is a syndrome that is the consequence of a tumor in the body. It is specifically due to the production of chemical signaling molecules by tumor cells or by an immune response against the tumor. Unlike a mass effect, it is not due to the local presence of cancer cells.

<span class="mw-page-title-main">Leptomeningeal cancer</span> Medical condition

Leptomeningeal cancer is a rare complication of cancer in which the disease spreads from the original tumor site to the meninges surrounding the brain and spinal cord. This leads to an inflammatory response, hence the alternative names neoplastic meningitis (NM), malignant meningitis, or carcinomatous meningitis. The term leptomeningeal describes the thin meninges, the arachnoid and the pia mater, between which the cerebrospinal fluid is located. The disorder was originally reported by Eberth in 1870. It is also known as leptomeningeal carcinomatosis, leptomeningeal disease (LMD), leptomeningeal metastasis, meningeal metastasis and meningeal carcinomatosis.

<span class="mw-page-title-main">Pineocytoma</span> Benign tumor of the pineal gland

Pineocytoma, is a rare, benign, slowly growing tumor of the pineal gland. The pineal gland is a small endocrine gland close to the center of the brain that secretes melatonin into the bloodstream. Pineocytomas can cause pressure and fluid build-up in the brain. They are more common in adults. Symptoms include vision problems, nausea, vomiting, memory problems, and headaches.

<span class="mw-page-title-main">Bonnet–Dechaume–Blanc syndrome</span> Medical condition

Bonnet–Dechaume–Blanc syndrome, also known as Wyburn-Mason syndrome, is a rare congenital disorder characterized by arteriovenous malformations of the brain, retina or facial nevi. The syndrome has a number of possible symptoms and can, more rarely, affect the skin, bones, kidneys, muscles, and gastrointestinal tract. When the syndrome affects the brain, people can experience severe headaches, seizures, acute stroke, meningism, and progressive neurological deficits due to acute or chronic ischaemia caused by arteriovenous shunting.

<span class="mw-page-title-main">Brain metastasis</span> Cancer that has metastasized (spread) to the brain from another location in the body

A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor. The metastasis typically shares a cancer cell type with the original site of the cancer. Metastasis is the most common cause of brain cancer, as primary tumors that originate in the brain are less common. The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer. Brain metastases can occur months or even years after the original or primary cancer is treated. Brain metastases have a poor prognosis for cure, but modern treatments allow patients to live months and sometimes years after the diagnosis.

Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are very dangerous and life-threatening. Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiforme, and high-grade astrocytoma/oligodendroglioma are among the worst. In these cases, untreated survival usually amounts to only a few months, and survival with current radiation and chemotherapy treatments may extend that time from around a year to a year and a half, possibly two or more, depending on the patient's condition, immune function, treatments used, and the specific type of malignant brain neoplasm. Surgery may in some cases be curative, but, as a general rule, malignant brain cancers tend to regenerate and emerge from remission easily, especially highly malignant cases. In such cases, the goal is to excise as much of the mass and as much of the tumor margin as possible without endangering vital functions or other important cognitive abilities. The Journal of Neuro-Oncology is the longest continuously published journal in the field and serves as a leading reference to those practicing in the area of neuro-oncology.

Embryonal rhabdomyosarcoma (EMRS) is a rare histological form of cancer in the connective tissue wherein the mesenchymally-derived cells (rhabdomyoblasts) resemble the primitive developing skeletal muscle of the embryo. It is the most common soft tissue sarcoma occurring in children. Embryonal rhabdomyosarcoma is also known as PAX-fusion negative or fusion-negative rhabdomyosarcoma, as tumors of this subtype are unified by their lack of a PAX3-FOXO1 fusion oncogene. Fusion status refers to the presence or absence of a fusion gene, which is a gene formed from joining two different genes together through DNA rearrangements. These types of tumors are classified as embryonal rhabdomyosarcoma "because of their remarkable resemblance to developing embryonic and fetal skeletal muscle."

Trilateral retinoblastoma (TRb) is a malignant midline primitive neuroectodermal tumor occurring in patients with inherited uni- or bilateral retinoblastoma. In most cases trilateral retinoblastoma presents itself as pineoblastoma. In about a fourth of the cases the tumor develops in another intracranial region, most commonly supra- or parasellar, but there are reported cases with non-pineal TRb in the 3rd ventricle. In most cases pineal TRb is diagnosed before the age of 5, but after the diagnosis of retinoblastoma. Non-pineal TRb, however, is often diagnosed simultaneous with retinoblastoma. Prognosis of patients with trilateral retinoblastoma is dismal, only a few patients have survived more than 5 years after diagnosis; all survivors were diagnosed with small tumors in a subclinical stage. Recent advances in (high-dose) chemotherapy treatment regimens and early detection have improved survival of patients with trilateral retinoblastoma.

<span class="mw-page-title-main">Central nervous system primitive neuroectodermal tumor</span> Medical condition

A central nervous system primitive neuroectodermal tumor, often abbreviated as PNET, supratentorial PNET, or CNS-PNET, is one of the 3 types of embryonal central nervous system tumors. It is considered an embryonal tumor because it arises from cells partially differentiated or still undifferentiated from birth. Those cells are usually neuroepithelial cells, stem cells destined to turn into glia or neurons. It can occur anywhere within the spinal cord and cerebrum and can have multiple sites of origins, with a high probability of metastasis through cerebrospinal fluid (CSF).

Embryonal tumor with multilayered rosettes (ETMR) is an embryonal central nervous system tumor. It is considered an embryonal tumor because it arises from cells partially differentiated or still undifferentiated from birth, usually neuroepithelial cells, stem cells destined to turn into glia or neurons. It can occur anywhere within the brain and can have multiple sites of origins, with a high probability of metastasis through cerebrospinal fluid (CSF). Metastases outside the central nervous system have been reported, but remain rare.

References

  1. 1 2 3 "Pineoblastoma". St. Jude Children's Research Hospital . Retrieved Mar 8, 2023.
  2. 1 2 3 4 Mayo Clinic Staff. "Brain Tumor: Pineoblastoma". Mayo Clinic . Retrieved 18 April 2022.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 Sin-Chan P, Li BK, Ho B, Fonseca A, Huang A (July 2018). "Molecular Classification and Management of Rare Pediatric Embryonal Brain Tumors". Current Oncology Reports. 20 (9): 69. doi:10.1007/s11912-018-0717-7. PMID   29995179.
  4. 1 2 3 4 5 Tamrazi B, Nelson M, Blüml S (February 2017). "Pineal Region Masses in Pediatric Patients". Neuroimaging Clinics of North America. 27 (1): 85–97. doi:10.1016/j.nic.2016.08.002. PMID   27889025.
  5. ↑ Greppin K, Cioffi G, Waite KA, Ostrom QT, Landi D, Takaoka K, et al. (April 2022). "Epidemiology of pineoblastoma in the United States, 2000-2017". Neuro-Oncology Practice. 9 (2): 149–157. doi:10.1093/nop/npac009. PMC   8965073 . PMID   35371520.
  6. ↑ "Pineal Region Tumors Diagnosis and Treatment - NCI". www.cancer.gov. 2018-09-17. Retrieved 2022-10-11.
  7. 1 2 Blessing MM, Alexandrescu S (June 2020). "Embryonal Tumors of the Central Nervous System: An Update". Surgical Pathology Clinics. 13 (2): 235–247. doi:10.1016/j.path.2020.01.003. PMID   32389264.
  8. ↑ Schultz KA, Stewart DR, Kamihara J, Bauer AJ, Merideth MA, Stratton P, et al. (1993). "DICER1 Tumor Predisposition". In Adam MP, Everman DB, Mirzaa GM, Pagon RA (eds.). GeneReviews®. Seattle (WA): University of Washington, Seattle. PMID   24761742 . Retrieved 2022-10-11.
  9. ↑ Provenzale JM, Weber AL, Klintworth GK, McLendon RE (January 1995). "Radiologic-pathologic correlation. Bilateral retinoblastoma with coexistent pinealoblastoma (trilateral retinoblastoma)". AJNR. American Journal of Neuroradiology. 16 (1): 157–165. PMC   8337708 . PMID   7900586.
  10. 1 2 de Jong MC, Kors WA, de Graaf P, Castelijns JA, Moll AC, Kivelä T (December 2015). "The Incidence of Trilateral Retinoblastoma: A Systematic Review and Meta-Analysis". American Journal of Ophthalmology. 160 (6): 1116–1126.e5. doi:10.1016/j.ajo.2015.09.009. hdl: 10138/223832 . PMID   26374932.
  11. ↑ Kivelä T (June 1999). "Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma". Journal of Clinical Oncology. 17 (6): 1829–1837. doi:10.1200/JCO.1999.17.6.1829. PMID   10561222.
  12. ↑ "Pineoblastoma - About the Disease - Genetic and Rare Diseases Information Center". rarediseases.info.nih.gov. Retrieved 2022-10-06.
  13. 1 2 3 4 5 6 7 Amato-Watkins AC, Lammie A, Hayhurst C, Leach P (2016-01-02). "Pineal parenchymal tumours of intermediate differentiation - An evidence-based review of a new pathological entity". British Journal of Neurosurgery. 30 (1): 11–15. doi:10.3109/02688697.2015.1096912. PMID   26571134.
  14. ↑ "Pineoblastoma". www.stjude.org. Retrieved 2022-10-05.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.